iRhythm Technologies (iRhythm Technologies) ROCE % : -30.05% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is iRhythm Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. iRhythm Technologies's annualized ROCE % for the quarter that ended in Mar. 2024 was -30.05%.

iRhythm Technologies ROCE % Historical Data

The historical data trend for iRhythm Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iRhythm Technologies ROCE % Chart

iRhythm Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-30.97

-12.02

-24.31

-30.44

-34.75

iRhythm Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-43.58	-20.52	-30.69	-45.24	-30.05

iRhythm Technologies ROCE % Calculation

iRhythm Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-119.006	/	( ( (448.222 - 89.096)	+	(433.144 - 107.37) )	/ 2 )
	=	-119.006	/	( (359.126	+	325.774)	/ 2 )
	=	-119.006	/	342.45
	=	-34.75 %

iRhythm Technologies's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-171.1	/	( ( (433.144 - 107.37)	+	(909.755 - 96.841) )	/ 2 )
	=	-171.1	/	( ( 325.774	+	812.914 )	/ 2 )
	=	-171.1	/	569.344
	=	-30.05 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

iRhythm Technologies (NAS:IRTC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

iRhythm Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of iRhythm Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

iRhythm Technologies (iRhythm Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRhythm Technologies Inc (NAS:IRTC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

I25:Germany

Address

699 8th Street, Suite 600, San Francisco, CA, USA, 94103

Website

https://www.irhythmtech.com

iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio include ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for up to 14 consecutive days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.

Executives

Daniel G. Wilson	officer: EVP, Strategy Corp Dev Inv Rel	699 8TH STREET, SUITE 600, SAN FRANCISCO CA 94103
Patrick Michael Murphy	officer: CLO & EVP RA/QA MrktAcs & Gov	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Mervin Smith	officer: EVP Strategic Business Ops	C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Marc W. Rosenbaum	officer: Chief Accounting Officer	7475 LUSK BLVD., SAN DIEGO CA 92121
Brice Bobzien	officer: Chief Financial Officer	C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Chad Patterson	officer: Chief Commercial Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Minang Turakhia	officer: EVP, CMO & CSO	C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Quentin S. Blackford	director, officer: President and CEO	7475 LUSK BLVD., SAN DIEGO CA 92121
Mojdeh Poul	director	3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST PAUL MN 55144-1000
Brian B Yoor	director	100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064
Mark J. Day	officer: EVP, Research & Development	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Douglas Devine	officer: Chief Financial Officer	C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH STREET, SUITE 600, SAN FRANCISCO CA 94103
Bairey Merz Cathleen Noel	director	16664 CUMBRE VERDE COURT, PACIFIC PALISADES CA 90272
Reyna M Fernandez	officer: EVP, Chief HR Officer	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Sumi Shrishrimal	officer: EVP, Chief Risk Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121